Alembic Pharmaceuticals Ltd — earnings calls

Alembic Pharmaceuticals reported consolidated revenue growth of 26% year-on-year in Q1 FY27, driven by 37% growth in International Generics, 33% growth in the API business and 7% growth in the India branded business. Management raised its full-year FY27 revenue growth outlook to the mid-teen range from an earlier low double-digit expectation, citing stronger than expected US Generics performance including the launch of Bosutinib. EBITDA grew 21% year-on-year to Rs 348 crore with a 16% margin, while profit after tax grew 12% to Rs 173 crore reflecting a higher effective tax rate following migration to the new tax regime.

Alembic Pharmaceuticals reported Q4 FY26 revenue of Rs 1,838 crores, up 4% year-on-year, with EBITDA before R&D at Rs 455 crores, up about 8%. For the full year, revenue grew 10% and reported profit after tax grew 16% to Rs 675 crores. Management discussed a drag from the newly launched U.S. branded product Pivya and outlined a directional outlook for FY27 including low double-digit consolidated revenue growth and R&D spend of Rs 750-800 crores.